292 related articles for article (PubMed ID: 18331231)
1. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease.
Chen X; Walker DG; Schmidt AM; Arancio O; Lue LF; Yan SD
Curr Mol Med; 2007 Dec; 7(8):735-42. PubMed ID: 18331231
[TBL] [Abstract][Full Text] [Related]
2. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.
Yan SS; Chen D; Yan S; Guo L; Du H; Chen JX
Front Biosci (Schol Ed); 2012 Jan; 4(1):240-50. PubMed ID: 22202057
[TBL] [Abstract][Full Text] [Related]
3. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?
Yan SD; Bierhaus A; Nawroth PP; Stern DM
J Alzheimers Dis; 2009; 16(4):833-43. PubMed ID: 19387116
[TBL] [Abstract][Full Text] [Related]
4. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.
Fang F; Lue LF; Yan S; Xu H; Luddy JS; Chen D; Walker DG; Stern DM; Yan S; Schmidt AM; Chen JX; Yan SS
FASEB J; 2010 Apr; 24(4):1043-55. PubMed ID: 19906677
[TBL] [Abstract][Full Text] [Related]
5. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
Lue LF; Yan SD; Stern DM; Walker DG
Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.
Leclerc E; Sturchler E; Vetter SW; Heizmann CW
Rev Neurosci; 2009; 20(2):95-110. PubMed ID: 19774788
[TBL] [Abstract][Full Text] [Related]
7. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity.
Sturchler E; Galichet A; Weibel M; Leclerc E; Heizmann CW
J Neurosci; 2008 May; 28(20):5149-58. PubMed ID: 18480271
[TBL] [Abstract][Full Text] [Related]
8. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.
Deane R; Singh I; Sagare AP; Bell RD; Ross NT; LaRue B; Love R; Perry S; Paquette N; Deane RJ; Thiyagarajan M; Zarcone T; Fritz G; Friedman AE; Miller BL; Zlokovic BV
J Clin Invest; 2012 Apr; 122(4):1377-92. PubMed ID: 22406537
[TBL] [Abstract][Full Text] [Related]
9. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.
Schmidt AM; Sahagan B; Nelson RB; Selmer J; Rothlein R; Bell JM
Curr Opin Investig Drugs; 2009 Jul; 10(7):672-80. PubMed ID: 19579173
[TBL] [Abstract][Full Text] [Related]
10. Aβ₁₋₄₂-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca²⁺-calcineurin signaling.
Kook SY; Hong HS; Moon M; Ha CM; Chang S; Mook-Jung I
J Neurosci; 2012 Jun; 32(26):8845-54. PubMed ID: 22745485
[TBL] [Abstract][Full Text] [Related]
11. RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity.
Fang F; Yu Q; Arancio O; Chen D; Gore SS; Yan SS; Yan SF
Hum Mol Genet; 2018 Mar; 27(6):1002-1014. PubMed ID: 29329433
[TBL] [Abstract][Full Text] [Related]
12. Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease.
Zhang L; Postina R; Wang Y
Cell Mol Life Sci; 2009 Dec; 66(24):3923-35. PubMed ID: 19672558
[TBL] [Abstract][Full Text] [Related]
13. Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide.
Yan SD; Roher A; Chaney M; Zlokovic B; Schmidt AM; Stern D
Biochim Biophys Acta; 2000 Jul; 1502(1):145-57. PubMed ID: 10899440
[TBL] [Abstract][Full Text] [Related]
14. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.
Deane R; Zlokovic BV
Curr Alzheimer Res; 2007 Apr; 4(2):191-7. PubMed ID: 17430246
[TBL] [Abstract][Full Text] [Related]
15. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.
Lue LF; Walker DG; Brachova L; Beach TG; Rogers J; Schmidt AM; Stern DM; Yan SD
Exp Neurol; 2001 Sep; 171(1):29-45. PubMed ID: 11520119
[TBL] [Abstract][Full Text] [Related]
16. The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells.
Du H; Li P; Wang J; Qing X; Li W
Cell Mol Neurobiol; 2012 Jan; 32(1):141-7. PubMed ID: 21837459
[TBL] [Abstract][Full Text] [Related]
17. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature.
Carnevale D; Mascio G; D'Andrea I; Fardella V; Bell RD; Branchi I; Pallante F; Zlokovic B; Yan SS; Lembo G
Hypertension; 2012 Jul; 60(1):188-97. PubMed ID: 22615109
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.
Sasaki N; Toki S; Chowei H; Saito T; Nakano N; Hayashi Y; Takeuchi M; Makita Z
Brain Res; 2001 Jan; 888(2):256-262. PubMed ID: 11150482
[TBL] [Abstract][Full Text] [Related]
19. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.
Deane R; Bell RD; Sagare A; Zlokovic BV
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):16-30. PubMed ID: 19275634
[TBL] [Abstract][Full Text] [Related]
20. Is RAGE still a therapeutic target for Alzheimer's disease?
Deane RJ
Future Med Chem; 2012 May; 4(7):915-25. PubMed ID: 22571615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
